2018年系统性红斑狼疮研究新进展

doi:10.35541/cjd.20190298

中华皮肤科杂志 ›› 2020, Vol. 53 ›› Issue (8): 665-667.doi: 10.35541/cjd.20190298

2018年系统性红斑狼疮研究新进展

罗帅寒天龙海陆前进

中南大学湘雅二医院皮肤科，长沙 410011

收稿日期:2019-02-13 修回日期:2019-06-21 发布日期:2020-07-31
通讯作者: 陆前进 E-mail:qianlu5860@gmail.com
基金资助:
国家自然科学基金（81703133、81773334）；湖南省科技创新计划项目（2018RS3031）；长沙市科技计划项目（KQ1802002）

Advances in systemic lupus erythematosus in 2018

Luo Shuaihantian, Long Hai, Lu Qianjin

Department of Dermatology, The Second Xiangya Hospital of Central South University, Changsha 410011, China

Received:2019-02-13 Revised:2019-06-21 Published:2020-07-31
Contact: Lu Qianjin E-mail:qianlu5860@gmail.com
Supported by:
National Natural Science Foundation of China（81703133, 81773334）; Hunan Science and Technology Innovation Project （2018RS3031）; Changsha Science and Technology Planting Project （KQ1802002）

摘要/Abstract

摘要： 【摘要】系统性红斑狼疮是一种主要累及中青年女性的复杂自身免疫疾病，临床表现多样，发病机制复杂。对于系统性红斑狼疮的研究一直是国内外自身免疫疾病领域的热点，本文主要综述2018年系统性红斑狼疮的基因组学与临床研究取得的新成果和进展。

关键词: 红斑狼疮, 系统性, 基因组学, 临床试验

Abstract: 【Abstract】 Systemic lupus erythematosus （SLE） is a complex autoimmune disease mainly involving young and middle-aged women, with various clinical manifestations and complicated pathogenesis. Research on SLE has always been a hot spot in the field of autoimmune diseases. This review summarizes new achievements and advances in genomics and clinical trials in SLE in 2018.

Key words: Lupus erythematosus, systemic, Genomics, Clinical trial

罗帅寒天龙海陆前进. 2018年系统性红斑狼疮研究新进展[J]. 中华皮肤科杂志, 2020,53(8):665-667. doi:10.35541/cjd.20190298

Luo Shuaihantian, Long Hai, Lu Qianjin. Advances in systemic lupus erythematosus in 2018[J]. Chinese Journal of Dermatology, 2020, 53(8): 665-667.doi:10.35541/cjd.20190298

参考文献 29

［1］	Yen EY, Shaheen M, Woo J, et al. 46⁃year trends in systemic lupus erythematosus mortality in the United States, 1968 to 2013: a nationwide population⁃based study［J］. Ann Intern Med, 2017,167（11）:777⁃785. doi: 10.7326/M17⁃0102.
［2］	Yen EY, Singh RR. Brief report: lupus⁃an unrecognized leading cause of death in young females: a population⁃based study using nationwide death certificates, 2000 -2015［J］. Arthritis Rheumatol, 2018,70（8）:1251⁃1255. doi: 10.1002/art.40512.
［3］	Ward MM. Education level and mortality in systemic lupus erythematosus （SLE）: evidence of underascertainment of deaths due to SLE in ethnic minorities with low education levels［J］. Arthritis Rheum, 2004,51（4）:616⁃624. doi:10.1002/art.20526.
［4］	Zhao M, Sun Y, Gao F, et al. Epigenetics and SLE: RFX1 downregulation causes CD11a and CD70 overexpression by altering epigenetic modifications in lupus CD4+ T cells［J］. J Autoimmun, 2010,35（1）:58⁃69. doi:10.1016/j.jaut.2010.02.002.
［5］	Zhao M, Tan Y, Peng Q, et al. IL⁃6/STAT3 pathway induced deficiency of RFX1 contributes to Th17⁃dependent autoimmune diseases via epigenetic regulation［J］. Nat Commun, 2018,9（1）:583. doi: 10.1038/s41467⁃018⁃02890⁃0.
［6］	Gorji AE, Roudbari Z, Alizadeh A, et al. Investigation of systemic lupus erythematosus （SLE） with integrating transcriptomics and genome wide association information［J］. Gene, 2019,706:181⁃187. doi:10.1016/j.gene.2019.05.004.
［7］	Wang YF, Zhang Y, Zhu Z, et al. Identification of ST3AGL4, MFHAS1, CSNK2A2 and CD226 as loci associated with systemic lupus erythematosus （SLE） and evaluation of SLE genetics in drug repositioning［J］. Ann Rheum Dis, 2018,77（7）:1078⁃1084. doi: 10.1136/annrheumdis⁃2018⁃213093.
［8］	Lim J, Bae SC, Kim K. Understanding HLA associations from SNP summary association statistics［J］. Sci Rep, 2019,9（1）:1337. doi: 10.1038/s41598⁃018⁃37840⁃9.
［9］	Chen X, Sun X, Yang W, et al. An autoimmune disease variant of IgG1 modulates B cell activation and differentiation［J］. Science, 2018,362（6415）:700⁃705. doi: 10.1126/science.aap 9310.
［10］	Urowitz MB, Bookman AA, Koehler BE, et al. The bimodal mortality pattern of systemic lupus erythematosus［J］. Am J Med, 1976,60（2）:221⁃225.
［11］	Bengtsson C, Ohman ML, Nived O, et al. Cardiovascular event in systemic lupus erythematosus in northern Sweden: incidence and predictors in a 7⁃year follow⁃up study［J］. Lupus, 2012,21（4）:452⁃459. doi: 10.1177/0961203311425524.
［12］	Schoenfeld SR, Kasturi S, Costenbader KH. The epidemiology of atherosclerotic cardiovascular disease among patients with SLE: a systematic review［J］. Semin Arthritis Rheum, 2013,43（1）:77⁃95. doi:10.1016/j.semarthrit.2012.12.002.
［13］	Manzi S, Meilahn EN, Rairie JE, et al. Age⁃specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study［J］. Am J Epidemiol, 1997,145（5）:408⁃415. doi: 10.1093/oxfordjournals.aje.a009122.
［14］	Leonard D, Svenungsson E, Dahlqvist J, et al. Novel gene variants associated with cardiovascular disease in systemic lupus erythematosus and rheumatoid arthritis［J］. Ann Rheum Dis, 2018,77（7）:1063⁃1069. doi: 10.1136/annrheumdis⁃2017⁃212614.
［15］	Tsai F, Homan PJ, Agrawal H, et al. Bim suppresses the development of SLE by limiting myeloid inflammatory responses［J］. J Exp Med, 2017,214（12）:3753⁃3773. doi:10.1084/jem. 20170479.
［16］	Antignani A, Segal D, Simon N, et al. Essential role for Bim in mediating the apoptotic and antitumor activities of immunotoxins［J］. Oncogene, 2017,36（35）:4953⁃4962. doi: 10.1038/onc.2017. 111.
［17］	Shukla S, Saxena S, Singh BK, et al. BH3⁃only protein BIM: an emerging target in chemotherapy［J］. Eur J Cell Biol, 2017,96（8）:728⁃738. doi: 10.1016/j.ejcb.2017.09.002.
［18］	Larosa M, Zen M, Gatto M, et al. IL⁃12 and IL⁃23/Th17 axis in systemic lupus erythematosus［J］. Exp Biol Med （Maywood）, 2019,244（1）:42⁃51. doi: 10.1177/1535370218824547.
［19］	van Vollenhoven RF, Hahn BH, Tsokos GC, et al. Efficacy and safety of ustekinumab, an IL⁃12 and IL⁃23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double⁃blind, phase 2, randomised, controlled study［J］. Lancet, 2018,392（10155）:1330⁃1339. doi: 10.1016/S0140⁃6736（18）32167⁃6.
［20］	Hahn BH. Belimumab for systemic lupus erythematosus［J］. N Engl J Med, 2013,368（16）:1528⁃1535. doi: 10.1056/NEJMct120 7259.
［21］	Zhang F, Bae SC, Bass D, et al. A pivotal phase III, randomised, placebo⁃controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea［J］. Ann Rheum Dis, 2018,77（3）:355⁃363. doi: 10.1136/annrheumdis⁃2017⁃211631.
［22］	Markham A. Baricitinib: first global approval［J］. Drugs, 2017,77（6）:697⁃704. doi:10.1007/s40265⁃017⁃0723⁃3.
［23］	Taylor PC, Keystone EC, van der Heijde D, et al. Baricitinib versus placebo or adalimumab in rheumatoid arthritis［J］. N Engl J Med, 2017,376（7）:652⁃662. doi: 10.1056/NEJMoa160 8345.
［24］	Richez C, Truchetet ME, Kostine M, et al. Efficacy of baricitinib in the treatment of rheumatoid arthritis［J］. Expert Opin Pharmacother, 2017,18（13）:1399⁃1407. doi:10.1080/14656566.2017.1359256.
［25］	Wallace DJ, Furie RA, Tanaka Y, et al. Baricitinib for systemic lupus erythematosus: a double⁃blind, randomised, placebo⁃controlled, phase 2 trial［J］. Lancet, 2018,392（10143）:222⁃231. doi:10.1016/S0140⁃6736（18）31363⁃1.
［26］	Werth VP, Merrill JT. A double⁃blind, randomized, placebo⁃controlled, phase II trial of baricitinib for systemic lupus erythematosus: how to optimize lupus trials to examine effects on cutaneous lupus erythematosus［J］. Br J Dermatol, 2019,180（5）:964⁃965. doi:10.1111/bjd.17344.
［27］	Dispenza MC, Regan JA, Bochner BS. Potential applications of Bruton′s tyrosine kinase inhibitors for the prevention of allergic reactions［J］. Expert Rev Clin Immunol, 2017,13（10）:921⁃923. doi: 10.1080/1744666X.2017.1370374.
［28］	Seiler T, Dreyling M. Bruton′s tyrosine kinase inhibitors in B⁃cell lymphoma: current experience and future perspectives［J］. Expert Opin Investig Drugs, 2017,26（8）:909⁃915. doi: 10.1080/13543784.2017.1349097.
［29］	Chalmers SA, Glynn E, Garcia SJ, et al. BTK inhibition ameliorates kidney disease in spontaneous lupus nephritis［J］. Clin Immunol, 2018,197:205⁃218. doi:10.1016/j.clim.2018.10. 008.

[1]	周彤耿松梅. 生物制剂在大疱性类天疱疮治疗中的应用[J]. 中华皮肤科杂志, 2023, 56(8): 789-793.
[2]	罗帅寒天龙海陆前进. 2022年系统性红斑狼疮研究新进展[J]. 中华皮肤科杂志, 2023, 56(3): 266-269.
[3]	林子沅庞天怡武静文靳慧. 多环芳烃在炎症性皮肤病发生发展中的作用研究进展[J]. 中华皮肤科杂志, 2023, 0(2): 20220271-e20220271.
[4]	王琪坚哲. 间充质干细胞三维培养技术及其在皮肤病治疗中的应用进展[J]. 中华皮肤科杂志, 2023, 0(2): 20230083-e20230083.
[5]	蒋佳怡王大光. 系统性疾病致甲改变机制研究进展[J]. 中华皮肤科杂志, 2023, 0(2): 20220078-e20220078.
[6]	胡颖焦晴晴. 记忆性T细胞在慢性自身免疫性皮肤病中的研究进展[J]. 中华皮肤科杂志, 2023, 0(2): 20230193-e20230193.
[7]	万立陈金波姜倩陈红英胡彬陈柳青. 反射式共聚焦显微镜在界面皮炎中的应用研究进展[J]. 中华皮肤科杂志, 2023, 56(10): 982-985.
[8]	中国医师协会皮肤科医师分会自身免疫病专业委员会 . 【开放获取】环孢素治疗免疫相关性皮肤病专家建议[J]. 中华皮肤科杂志, 2022, 55(6): 471-479.
[9]	罗帅寒天龙海陆前进, . 2021年系统性红斑狼疮研究新进展[J]. 中华皮肤科杂志, 2022, 55(4): 369-372.
[10]	何素玲田歆梁景耀邵蕾李俊龙黄琼霄刘玉梅王建琴. 重度特应性皮炎患者急性期和缓解期皮肤微生态研究[J]. 中华皮肤科杂志, 2022, 55(4): 329-336.
[11]	中国医师协会皮肤科医师分会自身免疫性疾病学组. 环磷酰胺治疗自身免疫性皮肤病中国专家共识[J]. 中华皮肤科杂志, 2021, 54(9): 765-770.
[12]	梁高澎宋志强. 免疫球蛋白E型自身抗体在自身免疫相关皮肤病中的研究进展[J]. 中华皮肤科杂志, 2021, 54(6): 553-556.
[13]	罗帅寒天龙海陆前进. 2020年系统性红斑狼疮研究新进展[J]. 中华皮肤科杂志, 2021, 54(6): 542-545.
[14]	渠莉田苏惠春程波. 特应性皮炎与系统性疾病相关性的研究进展[J]. 中华皮肤科杂志, 2021, 54(5): 463-466.
[15]	罗帅寒天龙海张桂英陆前进. 2019年系统性红斑狼疮研究新进展[J]. 中华皮肤科杂志, 2021, 54(2): 183-186.

2018年系统性红斑狼疮研究新进展

Advances in systemic lupus erythematosus in 2018

PDF

PDF (Mobile)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 29

相关文章 15

Metrics

本文评价

推荐阅读 10